Antivenom Should NOT Be Given Prophylactically in Snakebite Without Evidence of Envenomation
Do not administer antivenom (ASV) based solely on the fact that a snakebite occurred—wait for objective signs of envenomation before treating. The 2024 AHA/Red Cross guidelines clearly state that "antivenom is not available for use in the first aid setting" and emphasize that "a person bitten by a snake that is venomous or might be venomous should seek prompt medical attention" 1. The definitive treatment is antivenom, but this is administered in a hospital setting based on clinical evidence of envenomation, not prophylactically in the field.
Key Clinical Approach
Immediate Actions (Pre-Hospital)
- Activate emergency services immediately for any venomous or possibly venomous snakebite (Class 1 recommendation) 1
- Rest and immobilize the bitten extremity
- Remove rings and constricting objects
- Minimize patient exertion to reduce systemic venom absorption
- Do NOT attempt field treatment with antivenom—this is a hospital-based intervention
Hospital-Based Decision Making
The critical question is not whether to give 1-2 vials prophylactically, but when to initiate antivenom based on clinical evidence of envenomation:
Indications for antivenom administration include:
- Hemostatic abnormalities: Bleeding, abnormal coagulation tests (WBCT, INR, aPTT)
- Neurotoxic signs: Ptosis, paralysis, respiratory compromise (especially with coral snakes)
- Systemic symptoms: Hypotension, shock, severe pain
- Progressive local tissue injury: Significant swelling, tissue necrosis
The Timing Imperative
Early antivenom administration (within 6-12 hours) significantly improves outcomes 2, 3, 4:
- Delayed administration (>12 hours) is associated with increased renal complications (RR: 2.88) 2
- Late antivenom (6-12 hours) effectively reverses coagulopathy, but very late administration (>12 hours) shows diminished effectiveness for some clotting parameters 3
- Early antivenom prevents irreversible effects like pre-synaptic neurotoxicity and myotoxicity that cannot be reversed once established 4
Dosing Strategy
When envenomation is confirmed, the evidence supports:
Initial dose: 2 vials minimum for documented envenomation 5, 6:
- One vial may be adequate only for minor envenomation
- The recommendation for single-vial dosing is "neither scientific nor safe" for moderate-to-severe cases 5
- A simplified protocol using 1 vial showed delayed bleeding cessation and higher re-administration rates (30% vs 7%) compared to standard 2-vial dosing 7
Reassess at 2,4,6,12, and 24 hours:
- Persistent or worsening bleeding → administer 2 additional vials
- Neurological deterioration → administer 4 vials 7
- Monitor for recurrent coagulopathy (occurs in up to 25% of cases)
Critical Pitfalls to Avoid
Do not give prophylactic antivenom without evidence of envenomation: Not all snakebites result in envenomation (20-30% are "dry bites")
Do not delay hospital transport to administer field antivenom: The guidelines explicitly state antivenom is not for first aid use 1
Do not underdose when envenomation is confirmed: Single vial dosing increases risk of treatment failure and need for re-dosing 7, 5
Do not wait for severe symptoms before initiating antivenom: Early systemic symptoms (nausea, vomiting, headache, abdominal pain) should prompt immediate consideration of antivenom 4
Beware of adverse reactions: Antivenom carries significant risk—19.9% adverse reaction rate with 21% of those being anaphylactic 8. This reinforces the need to treat only confirmed envenomation, not prophylactically.
Special Considerations
For coral snake bites (Elapidae): Recent evidence suggests empiric antivenom administration (without waiting for symptoms) was associated with 3-fold higher ICU admissions and significantly more adverse reactions compared to expectant management 8. This supports a wait-and-see approach even for confirmed coral snake bites if the patient is asymptomatic.
For pit viper bites (Crotalinae): The majority (>95%) of North American venomous snakebites 1. These require antivenom based on clinical evidence of cytotoxic effects (tissue injury, coagulopathy) rather than prophylactic administration.